Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study

Clinical Lymphoma, Myeloma and Leukemia · Published 2026-07-01 · DOI 10.1016/j.clml.2026.07.007

Free full text

Authors (40)

Léopoldine Lapierre, Lucie Laemmel, Emilie Bérard, Lucie Rigolot, Audrey Bidet, Jules Higué, Anne Banos, Guillaume Béziat, Ramzi Jeddi, Benoit Branco, Claire Calmettes, Noémie Gadaud, Martin Gauthier, Leila Ghenim, Gaelle Laboure, Clémentine Salvado, Reza Tabrizi, Joséphine Thomazeau, Willy Vaillant, Suzanne Tavitian, Laurent Balardy, Thibaut Leguay, Alban Canali, Emilie Klein, Audrey Sarry, Madeline Mougenot, Eva Baraniecki, Anne-Charlotte de Grande, Pierre Bories, Laetitia Largeaud, Maël Heiblig, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carré, Arnaud Pigneux, François Vergez, Sarah Bertoli, Pierre-Yves Dumas, Christian Recher

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Lapierre, L., Laemmel, L., Bérard, E., et al. (2026). Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.07.007

Related articles